Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

John Palacio-Cardona

John Palacio-Cardona

Universidad Santiago De Cali, Colombia

Title: The treatment of acne as a strategy to improve contraceptive adherence in Colombian young women

Biography

Biography: John Palacio-Cardona

Abstract

Colombia is a country with great natural resources. In recent years, great economic and political eff orts have been made to achieve change and emerge from underdevelopment. In public health, strategies have been designed to reduce teenage pregnancies, given that this phenomenon generates low schooling and an uncertain future. Despite the achievement of results, there is still a long way to go. One of the problems detected in teenage pregnancies is the low adherence to modern contraceptive therapies. As a way to encourage greater adherence to contraception, one of the initiatives of the Program of Health Promotion in Santiago de Cali University, was to highlight the benefi cial eff ect of some hormonal contraceptive therapies on acne. Th e aim of this study was to determine the clinical eff ect of facial acne management with ethinylestradiol 20 μg/dienogest 2 mg in a cohort of Colombian adult women. A cohort of 120 female university students was followed during 12 months. Th ese participants were enrolled in the sexual and reproductive health program of the Santiago de Cali University. Monthly monitoring of facial acne lesion count was performed. Relative changes in facial lesion count were identified. At the end of follow-up, the percentage of reduction of lesions was 94% and 23% of women had a 100% reduction in acne lesions. In conclusion, the continued use of the ethinylestradiol 20 μg/dienogest 2 mg COCPs reduced infl ammatory and non-infl ammatory acne lesions in reproductiveage women between 18 and 30 years of age with no severe acne.